PMID- 35174593
OWN - NLM
STAT- MEDLINE
DCOM- 20220506
LR  - 20220712
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 5
DP  - 2022 May
TI  - The efficacy and safety of dupilumab for the treatment of atopic dermatitis among 
      Chinese patients in clinical practice: A single-center retrospective study.
PG  - e15385
LID - 10.1111/dth.15385 [doi]
AB  - Little real-work data regarding the efficacy and safety of dupilumab in the 
      treatment of atopic dermatitis (AD) is available at present. To assess the 
      efficacy and safety of dupilumab at 12 weeks in the treatment of AD in clinical 
      routine clinical practice. A retrospective, single-centre study of adult patients 
      with moderate to severe AD treated with dupilumab for 12 weeks in China. In 
      total, 60 patients (48 male, 12 female; mean age: 53.2 +/- 15.6) were enrolled in 
      this retrospective study. These patients exhibited a mean AD disease course of 
      10.6 years (6.0), 30% exhibited a family history of allergies, and 31 (51.7%) had 
      one or more allergic comorbidities. Following dupilumab treatment for 12 weeks, 
      83.3% and 42% of patients had achieved EASI-50 and EASI-75, respectively. 
      Overall, adverse events (AEs) were reported by 15% of patients, with the most 
      common being conjunctivitis, injection site reactions, and herpes simplex virus 
      infections. Laboratory testing after 12 weeks revealed pronounced decreases in 
      both circulating eosinophil counts (from 0.6 (0.1-2.8) to 0.3 (0.1-9.7) 10(9) /L) 
      and total IgE concentrations (from 327 (2.46-2500) to 230 (47.6-2200) U/ml) in 
      these patients. These real-world data reaffirm the safety and efficacy of 
      dupilumab as a treatment for moderate-to-severe AD among Chinese patients in 
      clinical practice.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Li, Ying
AU  - Li Y
AUID- ORCID: 0000-0002-4041-2646
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Lu, Jiajing
AU  - Lu J
AUID- ORCID: 0000-0002-0827-0596
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Chen, Rongfen
AU  - Chen R
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Ding, Yangfeng
AU  - Ding Y
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Xu, Shuang
AU  - Xu S
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Zou, Ying
AU  - Zou Y
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Yi, Xuemei
AU  - Yi X
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
FAU - Shi, Yuling
AU  - Shi Y
AUID- ORCID: 0000-0002-1273-7881
AD  - Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University 
      School of Medicine, Shanghai, China.
AD  - Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220303
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized
MH  - *Dermatitis, Atopic/diagnosis/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - atopic dermatitis
OT  - dupilumab
OT  - efficacy
OT  - real word
OT  - safety
EDAT- 2022/02/18 06:00
MHDA- 2022/05/07 06:00
CRDT- 2022/02/17 05:41
PHST- 2022/02/09 00:00 [revised]
PHST- 2022/01/01 00:00 [received]
PHST- 2022/02/15 00:00 [accepted]
PHST- 2022/02/18 06:00 [pubmed]
PHST- 2022/05/07 06:00 [medline]
PHST- 2022/02/17 05:41 [entrez]
AID - 10.1111/dth.15385 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 May;35(5):e15385. doi: 10.1111/dth.15385. Epub 2022 Mar 3.